| Date Filed | Type | Description |
| 06/25/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/19/2018 |
SC 13D/A
| Sanofi reports a 100% stake in Ablynx NV |
| 06/19/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/12/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/12/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/25/2018 |
SC 13D
| Sanofi reports a 95.6% stake in Ablynx NV |
| 05/18/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/14/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/14/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/07/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/07/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 04/05/2018 |
20-F/A
| Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] |
| 04/04/2018 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 04/04/2018 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 03/29/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018 • Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 • Initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, Belgium - March 29, 2018 - Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX] announced today that on April 4, 2018, Sanofi will commence the previously announced tender offers to acquire all of the outstanding shares ), warrants and convertible bonds of Ablynx for: - EUR 45.00 per share or ADS - EUR 18.66 - EUR 41.79 per warrant 1 - EUR 393,700.78 per convertible bond 2 The tender offers, which are being made pursuant to the Heads of Agreement, date..." |
|
| 03/29/2018 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 03/27/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/26/2018 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/20/2018 |
SC 13D/A
| VAN HERK INVESTMENTS B.V. reports a 5% stake in Ablynx NV |
| 03/13/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/02/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/01/2018 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 02/27/2018 |
SC 13D/A
| VAN HERK INVESTMENTS B.V. reports a 8.6% stake in Ablynx NV |
| 02/20/2018 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 02/16/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 7 February 2018 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, has decided to resign from the Board of Directors with immediate effect for personal reasons. Having contributed to Ablynx's recent M&A activities, and served on the Board since 2013, Dr Hansen will now focus on other opportunities. He will be succeeded by Dr Russell G. Greig, acting as a permanent representative of Greig Biotechnology Global Consulting Inc., who has been a non-executive Director of Ablynx since 2012, and has been unanimously elected by the Ablynx Board as the new Chairman. Dr Greig is an industry veteran and is currently Chairman of AM Pharma and MedEye , Sa...",
"ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July 2017, focussed on developing and commercialising Nanobody ® -based therapeutics for the treatment of various immune-mediated inflammatory diseases. Under the terms of the agreement, Sanofi gains exclusive global rights to two additional multi-specific Nanobodies against selected targets and in return will pay Ablynx exercise fees totalling €13 million plus additional research funding. Multi-specific Nanobodies provide the ability to address different pathway o..." |
|
| 02/13/2018 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6.2% stake in Ablynx NV* |
| 02/13/2018 |
SC 13G
| FMR LLC reports a 10% stake in ABLYNX NV |
| 01/30/2018 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/29/2018 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/29/2018 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 01/29/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/23/2018 |
SC 13D
| VAN HERK INVESTMENTS B.V. reports a 10.2% stake in Ablynx NV |
| 01/08/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 8 January 2018 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Peter Fellner, who has served as Chairman since 2013 1 , has decided to resign from the Board with immediate effect for personal reasons. He will be succeeded by Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, who has been a Non-executive Director of Ablynx since November 2013, and has been unanimously elected by the Ablynx Board as the new Chairman. Dr Bo Jesper Hansen is a highly-accomplished industry veteran with significant expertise in orphan drug research and development, international marketing and commercialization and has extensive regulatory, pharmacovigilance, medical marketing and business development knowled..." |
|
| 12/21/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|